---
pmid: '24825348'
title: SIRT2 induces the checkpoint kinase BubR1 to increase lifespan.
authors:
- North BJ
- Rosenberg MA
- Jeganathan KB
- Hafner AV
- Michan S
- Dai J
- Baker DJ
- Cen Y
- Wu LE
- Sauve AA
- van Deursen JM
- Rosenzweig A
- Sinclair DA
journal: EMBO J
year: '2014'
full_text_available: false
pmcid: PMC4194088
doi: 10.15252/embj.201386907
---

# SIRT2 induces the checkpoint kinase BubR1 to increase lifespan.
**Authors:** North BJ, Rosenberg MA, Jeganathan KB, Hafner AV, Michan S, Dai J, Baker DJ, Cen Y, Wu LE, Sauve AA, van Deursen JM, Rosenzweig A, Sinclair DA
**Journal:** EMBO J (2014)
**DOI:** [10.15252/embj.201386907](https://doi.org/10.15252/embj.201386907)
**PMC:** [PMC4194088](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4194088/)

## Abstract

1. EMBO J. 2014 Jul 1;33(13):1438-53. doi: 10.15252/embj.201386907. Epub 2014 May
 12.

SIRT2 induces the checkpoint kinase BubR1 to increase lifespan.

North BJ(1), Rosenberg MA(2), Jeganathan KB(3), Hafner AV(1), Michan S(1), Dai 
J(2), Baker DJ(3), Cen Y(4), Wu LE(5), Sauve AA(4), van Deursen JM(3), 
Rosenzweig A(2), Sinclair DA(6).

Author information:
(1)Department of Genetics, Paul F. Glenn Laboratories for the Biological 
Mechanisms of Aging Harvard Medical School, Boston, MA, USA.
(2)Cardiovascular Division, Beth Israel Deaconess Medical Center Harvard Medical 
School, Boston, MA, USA.
(3)Department of Pediatric and Adolescent Medicine, Mayo Clinic College of 
Medicine, Rochester, MN, USA.
(4)Department of Pharmacology, Weill Medical College of Cornell University, New 
York, NY, USA.
(5)Department of Pharmacology, School of Medicine The University of New South 
Wales, Sydney, NSW, Australia.
(6)Department of Genetics, Paul F. Glenn Laboratories for the Biological 
Mechanisms of Aging Harvard Medical School, Boston, MA, USA Department of 
Pharmacology, School of Medicine The University of New South Wales, Sydney, NSW, 
Australia david_sinclair@hms.harvard.edu.

Comment in
    EMBO J. 2014 Jul 1;33(13):1417-9. doi: 10.15252/embj.201488983.

Mice overexpressing the mitotic checkpoint kinase gene BubR1 live longer, 
whereas mice hypomorphic for BubR1 (BubR1(H/H)) live shorter and show signs of 
accelerated aging. As wild-type mice age, BubR1 levels decline in many tissues, 
a process that is proposed to underlie normal aging and age-related diseases. 
Understanding why BubR1 declines with age and how to slow this process is 
therefore of considerable interest. The sirtuins (SIRT1-7) are a family of 
NAD(+)-dependent deacetylases that can delay age-related diseases. Here, we show 
that the loss of BubR1 levels with age is due to a decline in NAD(+) and the 
ability of SIRT2 to maintain lysine-668 of BubR1 in a deacetylated state, which 
is counteracted by the acetyltransferase CBP. Overexpression of SIRT2 or 
treatment of mice with the NAD(+) precursor nicotinamide mononucleotide (NMN) 
increases BubR1 abundance in vivo. Overexpression of SIRT2 in BubR1(H/H) animals 
increases median lifespan, with a greater effect in male mice. Together, these 
data indicate that further exploration of the potential of SIRT2 and NAD(+) to 
delay diseases of aging in mammals is warranted.

Â© 2014 The Authors.

DOI: 10.15252/embj.201386907
PMCID: PMC4194088
PMID: 24825348 [Indexed for MEDLINE]
